...read the wave

Nano Biz...in depth... im detail
www.nanoTsunami.com

 


Nanogen Issued Patent for Ligation-Based Strand Displacement Amplification Technologies
for DNA Analysis

SAN DIEGO, March 11 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN), developer of advanced diagnostic products, announced today that it was issued U.S. Patent No. 6,864,071, "Multiplex amplification and separation of nucleic acid sequences using ligation-dependent strand displacement amplification and bioelectronic chip technology," by the U.S. Patent and Trademark Office. The '071 patent relates to amplifying and analyzing multiple samples of nucleic acid using ligation-based strand displacement amplification (SDA) technologies. The intellectual property pertains to research Nanogen conducted in collaboration with Becton Dickinson and increases Nanogen's portfolio of technologies for multiplex amplification on a chip.

The combination of SDA and Nanogen chip technologies makes it possible to conduct multiplex amplification, detection and analysis of multiple samples within a single electronic microarray. Unlike techniques that rely on thermal cycling, SDA is an isothermal amplification process that utilizes a series of primers, DNA polymerase and a restriction enzyme to exponentially amplify the target nucleic acid sequence. The devices and methods of Nanogen's invention may be useful in a variety of applications, including disease diagnostics, genetic analyses, drug discovery, pharmacogenomics, and agricultural and environmental applications.

This new patent expands Nanogen's intellectual property portfolio to include 113 patents issued in the U.S.

About Nanogen, Inc.

Nanogen's advanced diagnostics provide physicians and patients worldwide with sophisticated information to predict, diagnose and treat disease. Research and clinical reference labs use the highly accurate and reliable NanoChip(R) Molecular Biology Workstation, NanoChip(R) Electronic Microarray and broad suite of analyte specific reagents to develop tests to detect infectious diseases, drug toxicity and mutations associated with cancer, cardiovascular and genetic diseases. The next generation instrument system, the NanoChip(R) 400, is expected to be available in 2005. Nanogen's subsidiary SynX offers a line of point-of-care diagnostic tests and is building expertise in cardiac related health conditions. Nanogen's ten years of pioneering research involving nanotechnology may also have future applications in medical diagnostics, biowarfare and other industries. For additional information please visit Nanogen's website at www.nanogen.com.

SOURCE Nanogen, Inc.

/CONTACT: Robert Saltmarsh, Chief Financial Officer of Nanogen, Inc.,
+1-858-410-4600; or Media & Investor Relations, Pam Lord of Atkins +
Associates, +1-858-527-3494, plord@irpr.com, for Nanogen, Inc./
/Web site: http://www.nanogen.com /
(NGEN)



www.nano-tsunami.com
This story has been adapted from a news release -
Diese Meldung basiert auf einer Pressemitteilung -
Deze tekst is gebaseerd op een nieuwsbericht -

 


who is reading
the wave ?

missed some news ?
click on archive photo

 

or how about joining us

 

or contacting us ?

 


about us

 

our mission